Copper is elevated in the blood/serum of nearly every disease state examined in this wiki:
| Disease | copper (Cu) Direction | Evidence |
|---|---|---|
| PCOS | Elevated | SMD = 0.51, p < 0.0001 (meta-analysis of 9 studies) |
| Breast cancer | Elevated | SMD 2.44 in plasma/serum |
| Lung cancer | Elevated | Disrupted copper-iron (Fe) and copper-zinc (Zn) correlations |
| Prostate cancer | Elevated | 1.69 vs 1.02 ug/mL, p < 0.005 |
| Pancreatic cancer | Elevated | Urinary copper significantly higher |
| AMI | Elevated | 0.85 vs 0.73 ug/mL, p < 0.01 |
| RA | Elevated | Highest blood copper among disease groups |
| IBD | Elevated | Positively associated with CRP |
Yet in neurodegenerative brain tissue, copper is DECREASED -- the most widespread metallomic alteration across DLB, AD, and PDD, with copper changes contributing the most to disease separation in PLS-DA models [1]Scholefield et al. 2024 — Brain Metallomic Signatures Distinguish DLB from AD and PDDMelissa Scholefield, Stephanie J. Church, Jingshu Xu et al. · 2024Open reference 1 ↓. AD brains show an additional paradox within the paradox: increased copper in amyloid plaques but decreased intracellular copper, suggesting a redistribution problem rather than simple excess or deficiency Copper.
Evidence map1 cited passagesInspect provenance +
Yet in neurodegenerative brain tissue, copper is DECREASED -- the most widespread metallomic alteration across DLB, AD, and PDD, with copper changes contributing the most to disease separation in PLS-DA models. AD brains show an additional paradox within the paradox: increased Cu in amyloid plaques but decreased intracellular Cu, suggesting a redistribution
Cause, Consequence, or Both?#
The central unresolved question: is elevated serum copper a CAUSE of these diseases, a CONSEQUENCE of the acute phase response (ceruloplasmin, which carries >90% of serum copper (Cu), is an acute-phase reactant that rises with any inflammation), or a MEDIATOR that both results from and amplifies disease?
If copper elevation is purely an acute-phase response, then it is a biomarker (useful for diagnosis) but not a therapeutic target. If it drives disease through cuproplasia (copper-dependent cell growth in cancer), metalloestrogen activity (contributing to PCOS), or Fenton-like redox cycling, then copper reduction could be therapeutic. The copper/zinc (Zn) ratio -- elevated across virtually all cancer types, PCOS, and AMI -- may capture the simultaneous copper accumulation and zinc depletion that characterizes systemic metal dyshomeostasis Copper, Zinc.
The Brain-Periphery Disconnect#
For neurodegeneration, the clinical dilemma is stark. Serum copper may be normal or elevated in AD patients, but brain copper is depleted. Copper supplementation to address brain deficiency could worsen peripheral disease. Copper chelation to address peripheral excess could worsen brain deficiency. The problem may not be total copper status but copper DISTRIBUTION -- and no current intervention can selectively redirect copper from the periphery to the brain.
Clinical Implication#
The copper (Cu)/zinc (Zn) ratio should be measured as part of metallomic profiling in patients with cancer, PCOS, or cardiovascular disease. However, interventions to modify copper status require clarity on whether the elevation is causal. For neurodegenerative disease, the focus should shift from total copper levels to copper distribution and trafficking, with ATP7A and ATP7B genotyping potentially informing personalized approaches.
References 1
Numbered by first appearance in the article, then reconciled with its declared source list.
- 1
★Melissa Scholefield, Stephanie J. Church, Jingshu Xu et al. (2024). Scholefield et al. 2024 — Brain Metallomic Signatures Distinguish DLB from AD and PDD. Frontiers in Neuroscience.